Cholesterol synthesis and gallstone formation are promoted by trimethylamine-N-oxide (TMAO), a derivative of trimethylamine, which is a metabolite of ...

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that binds to the LDL receptor on hepatocytes, promoting its internalization and degradation within the cell. [Repatha package ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis into a phase 3 programme, removing a competitor to Novartis' rival therapy Leqvio. Like Leqvio ...

The firm's Heart-2 study of VERVE-102, which is designed to inactivate the PCSK9 gene, is already underway in Canada and the UK.

Verve Therapeutics (VERV) announced the clearance of its Investigational New Drug application by the U.S. Food and Drug Administration for ...

The company expects next quarter to read out initial data from its Heart-2 trial, which is testing a one-time treatment for people with genetically elevated cholesterol.

However, more aggressive treatments may be needed too, such as injectable PCSK9 inhibitors, cholesterol absorption blockers, ...

Allergan was running a long-term study on silicone breast implants. I had always wanted a more feminine body like the girls in the magazines, so I joined and got implants. They never followed up with ...

This could soon be a thing of the past as a one-time injection could potentially silence the gene responsible for cholesterol, PCSK9. A new study found this worked just as well as current ...